Home>
US Stocks>
Protalix Biotherapeutics

Protalix Biotherapeutics share price today

(PLX)

Protalix Biotherapeutics share price is $1.76 & ₹149.56 as on 21 Dec 2024, 2.30 'hrs' IST

$1.76

▲

0.02

(1.15%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Protalix Biotherapeutics share price in Dollar and Rupees. Guide to invest in Protalix Biotherapeutics from India. Also see the sentimental analysis on Indian investors investing in Protalix Biotherapeutics. Get details on the Indian mutual funds that are investing in Protalix Biotherapeutics. Get Analyst recommendations and forecasts along with all the Protalix Biotherapeutics's financials.

Protalix Biotherapeutics share price movements

Today's Low: $1.69
Today's High: $1.79
$1.76
3.93%
Downside
Day's Volatility :5.27%
Upside
1.4%
52 Weeks Low: $0.82
52 Weeks High: $1.90
$1.76
53.33%
Downside
52 Weeks Volatility :56.77%
Upside
7.37%

Protalix Biotherapeutics Returns

Period	Protalix Biotherapeutics Inc	Index (Russel 2000)
3 Months	57.14%	0.0%
6 Months	36.43%	0.0%
1 Year	-4.35%	0.0%
3 Years	10.69%	-19.7%

Protalix Biotherapeutics Key Statistics

in dollars & INR

Previous Close	$1.74
Open	$1.69
Today's High	$1.785
Today's Low	$1.6909
Market Capitalization	$128.1M
Today's Volume	$344.1K
52 Week High	$1.9
52 Week Low	$0.8214
Revenue TTM	$38.1M
EBITDA	$-13.5M
Earnings Per Share (EPS)	$-0.15
Profit Margin	-38.62%
Quarterly Earnings Growth YOY	-0.39%
Return On Equity TTM	-43.49%

How to invest in Protalix Biotherapeutics from India?

It is very easy for Indian residents to invest directly in Protalix Biotherapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Protalix Biotherapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Protalix Biotherapeutics or PLX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Protalix Biotherapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Protalix Biotherapeutics shares which would translate to 0.483 fractional shares of Protalix Biotherapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Protalix Biotherapeutics, in just a few clicks!

Returns in Protalix Biotherapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Protalix Biotherapeutics investment value today

Current value as on today

₹1,06,544

Returns

₹6,544

(+6.54%)

Returns from Protalix Biotherapeutics Stock

₹4,348 (false-4.35%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Protalix Biotherapeutics

46%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Protalix Biotherapeutics on INDmoney from India has grown in the last 30 days as on Dec 22, 2024. 46% more investors are searching Protalix Biotherapeutics in the last 30 days versus the previous period.

Analyst Recommendation on Protalix Biotherapeutics

Buy

80%Buy

20%Hold

0%Sell

Based on 5 Wall street analysts offering stock ratings for Protalix Biotherapeutics(by analysts ranked 0 to 5 stars)

Based on 5 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Protalix Biotherapeutics

What analysts predicted

Upside of 695.45%

Current:

$1.76

Target:

$14.00

Insights on Protalix Biotherapeutics

Price Movement
In the last 3 months, PLX stock has moved up by 60.0%
Increasing Revenue
Revenue is up for the last 3 quarters, 3.74M → 17.95M (in $), with an average increase of 48.6% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -6.04M → 3.23M (in $), with an average increase of 102.7% per quarter
PLX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 34.4%
Price to Sales
ForPLX every $1 of sales, investors are willing to pay $3.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Protalix Biotherapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$34.2M	↑ 77.94%
Net Income	$-26.5M	↓ 68.97%
Net Profit Margin	-77.27%	↑ 365.91%

	FY19	Y/Y Change
Revenue	$54.7M	↑ 59.73%
Net Income	$-26.2M	↓ 0.81%
Net Profit Margin	-47.98%	↑ 29.29%

	FY20	Y/Y Change
Revenue	$62.9M	↑ 15.0%
Net Income	$-14.9M	↓ 43.25%
Net Profit Margin	-23.68%	↑ 24.3%

	FY21	Y/Y Change
Revenue	$38.4M	↓ 39.03%
Net Income	$-34.0M	↑ 128.21%
Net Profit Margin	-88.62%	↓ 64.94%

	FY22	Y/Y Change
Revenue	$47.6M	↑ 24.22%
Net Income	$-14.9M	↓ 56.08%
Net Profit Margin	-31.33%	↑ 57.29%

	FY23	Y/Y Change
Revenue	$65.5M	↑ 37.48%
Net Income	$8.3M	↓ 155.68%
Net Profit Margin	12.69%	↑ 44.02%

	Q2 FY23	Q/Q Change
Revenue	$35.1M	↑ 265.82%
Net Income	$19.3M	↓ 717.66%
Net Profit Margin	55.14%	↑ 87.8%

	Q3 FY23	Q/Q Change
Revenue	$10.3M	↓ 70.51%
Net Income	$-1.9M	↓ 109.58%
Net Profit Margin	-17.9%	↓ 73.04%

	Q4 FY23	Q/Q Change
Revenue	$10.5M	↑ 1.36%
Net Income	$-6.0M	↑ 226.35%
Net Profit Margin	-57.64%	↓ 39.74%

	Q1 FY24	Q/Q Change
Revenue	$3.7M	↓ 64.26%
Net Income	$-4.6M	↓ 23.97%
Net Profit Margin	-122.6%	↓ 64.96%

	Q2 FY24	Q/Q Change
Revenue	$13.5M	↑ 259.5%
Net Income	$-2.2M	↓ 52.06%
Net Profit Margin	-16.35%	↑ 106.25%

	Q3 FY24	Q/Q Change
Revenue	$18.0M	↑ 33.29%
Net Income	$3.2M	↓ 246.89%
Net Profit Margin	18.02%	↑ 34.37%

	FY18	Y/Y Change
Profit	$24.9M	↑ 521.74%

	FY19	Y/Y Change
Profit	$43.8M	↑ 75.63%

	FY20	Y/Y Change
Profit	$52.0M	↑ 18.78%

	FY21	Y/Y Change
Profit	$22.0M	↓ 57.71%

	FY22	Y/Y Change
Profit	$28.0M	↑ 27.48%

	FY23	Y/Y Change
Profit	$42.5M	↑ 51.58%

	Q2 FY23	Q/Q Change
Profit	$28.9M	↑ 344.83%

	Q3 FY23	Q/Q Change
Profit	$5.5M	↓ 81.15%

	Q4 FY23	Q/Q Change
Profit	$1.6M	↓ 70.1%

	Q1 FY24	Q/Q Change
Profit	$1.1M	↓ 29.69%

	Q2 FY24	Q/Q Change
Profit	$4.0M	↑ 250.61%

	Q3 FY24	Q/Q Change
Profit	$9.6M	↑ 138.53%

	FY18	Y/Y Change
Operating Cash Flow	$-7.7M	↓ 22.53%
Investing Cash Flow	$-591.0K	↓ 47.18%
Financing Cash Flow	$-4.8M	↑ 234.88%

	FY19	Y/Y Change
Operating Cash Flow	$-19.4M	↑ 150.04%
Investing Cash Flow	$-883.0K	↑ 49.41%
Financing Cash Flow	$46.5M	↓ 1077.84%

	FY20	Y/Y Change
Operating Cash Flow	$-26.1M	↑ 34.86%
Investing Cash Flow	$-20.0M	↑ 2159.57%
Financing Cash Flow	$46.5M	↑ 0.0%

	FY21	Y/Y Change
Operating Cash Flow	$-10.3M	↓ 60.6%
Investing Cash Flow	$18.9M	↓ 194.83%
Financing Cash Flow	$12.1M	↓ 74.01%

	FY22	Y/Y Change
Operating Cash Flow	$-25.0M	↑ 143.07%
Investing Cash Flow	$-5.0M	↓ 126.61%
Financing Cash Flow	$8.2M	↓ 31.79%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$5.0M	↓ 265.88%
Investing Cash Flow	$4.5M	↓ 4.69%
Financing Cash Flow	$10.4M	↓ 26.7%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-6.9M	↓ 238.51%
Investing Cash Flow	$-16.4M	↓ 462.95%
Financing Cash Flow	$24.7M	↑ 136.42%

Protalix Biotherapeutics Technicals Summary

Sell

Neutral

Buy

Protalix Biotherapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Protalix Biotherapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Protalix Biotherapeutics Inc	4.14%	36.43%	-4.35%	10.69%	10.69%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.38%	12.23%	86.41%
Biontech Se	4.48%	30.56%	7.97%	-55.71%	237.85%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.37%	26.29%	108.55%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-2.55%	77.79%	80.12%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Protalix Biotherapeutics Inc	13.0	NA	-0.1	0.0	-0.43	-0.1	NA	0.46
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Protalix Biotherapeutics Inc	Buy	$128.1M	10.69%	13.0	-38.62%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	86.41%	17.51	33.61%
Biontech Se	Buy	$26.7B	237.85%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	108.55%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.12%	32.84	-4.51%

About Protalix Biotherapeutics

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase

Organization	Protalix Biotherapeutics
Employees	208
CEO	Mr. Dror Bashan
Industry	Health Services

Management People of Protalix Biotherapeutics

Name	Title
Mr. Dror Bashan	President, CEO & Director
Mr. Eyal Rubin M.B.A.	Senior VP, CFO, Treasurer & Corporate Secretary
Mr. Yaron Naos	Senior Vice President of Operations
Ms. Yael Fellous	Vice President of Human Resources

Important FAQs about investing in Protalix Biotherapeutics from India :

What is Protalix Biotherapeutics share price today?

Protalix Biotherapeutics share price today stands at $1.76, Open: $1.69 ; Previous Close: $1.74 ; High: $1.79 ; Low: $1.69 ; 52 Week High: $1.90 ; 52 Week Low: $0.82. The stock opens at $1.69, after a previous close of $1.74. The stock reached a daily high of $1.79 and a low of $1.69, with a 52-week high of $1.90 and a 52-week low of $0.82.

Can Indians buy Protalix Biotherapeutics shares?

Yes, Indians can invest in the Protalix Biotherapeutics (PLX) from India.

With INDmoney, you can buy Protalix Biotherapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Protalix Biotherapeutics at zero transaction cost.

How can I buy Protalix Biotherapeutics shares from India?

It is very easy to buy Protalix Biotherapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Protalix Biotherapeutics be purchased?

Yes, you can buy fractional shares of Protalix Biotherapeutics with INDmoney app.

What are the documents required to start investing in Protalix Biotherapeutics stocks?

To start investing in Protalix Biotherapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.